Media

The following information is intended as a resource for journalists only and was factually correct at the time it was issued.

Lisa Maguire
Director, Communications and Patient Relations
Australia and New Zealand
+ 61 499 200 550
lisa.maguire@abbvie.com

Kate Richards
Head of Corporate Communications
Australia and New Zealand
+61 466 420 739    
kate.richards@abbvie.com

AbbVie Australia follows Medicines Australia’s Code of Conduct and the Therapeutic Goods Act.​ Both prohibit a pharmaceutical company from direct to consumer advertising which includes issuing media statements about our prescription medicines. We can issue statements to advise registration of a new medicine, a reimbursement notice of a medicine or news not related to our medicines.

2019

February


New targeted treatment option for patients with Chronic Lymphocytic Leukaemia (CLL) now available on the Pharmaceutical Benefits Scheme
Read full media release here.

2018

October

AbbVie Welcomes TGA Regulatory Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab
Read full media release here.

August

Eight-week Hepatitis C Treatment on Pharmaceutical Benefits scheme from 1st August 2018
Read full media release here.

April

Announcement: Venclexta PBS Status
Read full media release here.

February

Experts concerned Parksinon’s patients may be missing out on support in the Illawarra
Read full media release here.